Mark Lee Fernandes and Shi-Ming Lin contribute to this article equally.
Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program†
Article first published online: 7 DEC 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 103, Issue 2, pages 133–139, February 2011
How to Cite
Chen, W.-T., Fernandes, M. L., Lin, C.-C. and Lin, S.-M. (2011), Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. J. Surg. Oncol., 103: 133–139. doi: 10.1002/jso.21797
- Issue published online: 21 JAN 2011
- Article first published online: 7 DEC 2010
- Manuscript Accepted: 11 OCT 2010
- Manuscript Received: 17 AUG 2010
- hepatocellular carcinoma;
- radiofrequency ablation;
The aim of this study was to evaluate the impact of the interval between diagnosis and treatment using radiofrequency (RF) ablation on the survival of patients with HCC detected through a surveillance program.
Between January 2004 and July 2007, 121 cirrhotic patients with 157 tumours detected through a surveillance program underwent RF ablation. A delay in treatment was defined as >5 weeks. The mean length of follow-up was 25 months (range 8–55 months). Cumulative survival of patients was analysed using the Kaplan–Meier method. Cox regression models were used to identify factors associated with patient survival.
The 1-, 2- and 3-year survival rates were 92.5%, 78.5% and 67.2%. The independent predictors of poorer patient survival were time from diagnosis to treatment >5 weeks (pooled odds ratio [OR], 3.59; 95% confidence interval [CI], 1.58–8.18; P = 0.002), absence of complete ablation after the initial RF session (OR, 2.42; 95% CI 1.07–5.45; P = 0.033) and Child-Pugh B liver cirrhosis (OR, 2.46; 95% CI 1.06–5.70; P = 0.036).
Delay in the start of effective treatment for HCC using RF ablation may be associated with poorer patient survival. J. Surg. Oncol. 2011; 103:133–139. © 2010 Wiley-Liss, Inc.